Neutrogena Scalp Therapy Anti-dandruff Itchy Scalp
Salicylic Acid
Johnson & Johnson Consumer Inc.
Human Otc Drug
NDC 69968-0725Neutrogena Scalp Therapy Anti-dandruff Itchy Scalp also known as Salicylic Acid is a human otc drug labeled by 'Johnson & Johnson Consumer Inc.'. National Drug Code (NDC) number for Neutrogena Scalp Therapy Anti-dandruff Itchy Scalp is 69968-0725. This drug is available in dosage form of Shampoo. The names of the active, medicinal ingredients in Neutrogena Scalp Therapy Anti-dandruff Itchy Scalp drug includes Salicylic Acid - 25 mg/mL . The currest status of Neutrogena Scalp Therapy Anti-dandruff Itchy Scalp drug is Active.
Drug Information:
| Drug NDC: | 69968-0725 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Neutrogena Scalp Therapy Anti-dandruff Itchy Scalp |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Salicylic Acid |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Johnson & Johnson Consumer Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Shampoo |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | SALICYLIC ACID - 25 mg/mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 06 Dec, 2021 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 21 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part358H |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2024 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Johnson & Johnson Consumer Inc.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 2586423
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UPC: | 0070501103326
|
| UPC stands for Universal Product Code. |
| UNII: | O414PZ4LPZ
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 69968-0725-1 | 354 mL in 1 BOTTLE, PLASTIC (69968-0725-1) | 06 Dec, 2021 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purposes anti-dandruff, anti-seborrheic dermatitis, anti-psoriasis
Product Elements:
Neutrogena scalp therapy anti-dandruff itchy scalp salicylic acid menthol water sodium c14-16 olefin sulfonate cocamidopropyl betaine sodium chloride sodium citrate, unspecified form sodium lauroyl sarcosinate hexylene glycol linoleamidopropyl propylene glycol-dimonium chloride phosphate sodium hydroxide citric acid monohydrate salicylic acid salicylic acid
Indications and Usage:
Use controls the symptoms of dandruff, seborrheic dermatitis and psoriasis.
Warnings:
Warnings for external use only. ask a doctor before use if you have a condition that covers a large area of the body. when using this product avoid contact with the eyes. if contact occurs, rinse eyes thoroughly with water. stop use and ask a doctor if condition worsens or does not improve after regular use of this product as directed. keep out of reach of children . if swallowed, get medical help or contact a poison control center right away.
When Using:
When using this product avoid contact with the eyes. if contact occurs, rinse eyes thoroughly with water.
Dosage and Administration:
Directions for best results, use at least twice a week or as directed by a doctor. wet hair thoroughly. massage shampoo into your scalp. lather, leaving on your hair and scalp for a few minutes. rinse and repeat.
Stop Use:
Stop use and ask a doctor if condition worsens or does not improve after regular use of this product as directed.
Package Label Principal Display Panel:
Principal display panel - 354 ml bottle carton neutrogena scalp therapytm anti-dandruff medicated itchy scalp 2.5% salicylic acid shampoo with menthol neutrogena® dermatologist recommended brand 12 fl oz (354 ml) ntg001
Further Questions:
Questions? call 800-256-4247 or 215-273-8755 (collect) or visit www.neutrogena.com